https://www.pharmaradar360.com/article/june-m-a-recap-three-deals-three-billion-dollar-stories-02b7301895fa715fPharma Surgeen2026-07-29T10:06:54.000ZJune M&A recap: Three deals, three billion-dollar storieshttps://www.pharmaradar360.com/article/why-chinese-biotech-licensing-deals-became-attractive-to-us-investors-9ccbf2a2339710dcPharma Surgeen2026-07-29T10:04:53.000ZWhy Chinese Biotech Licensing Deals Became Attractive to US Investorshttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-march-2-30e801b2e4b499e7Pharma Surgeen2026-07-29T10:02:46.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: March 2026https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-jun-6e405552d2e63be0Pharma Surgeen2026-07-29T10:02:24.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: June 2026https://www.pharmaradar360.com/article/biotech-academy-gets-nearly-500k-for-boston-expansion-location-6b2ff9557e0a315aPharma Surgeen2026-07-29T10:00:00.000ZBiotech academy gets nearly $500k for Boston expansion locationhttps://www.pharmaradar360.com/article/zmiany-tak-ale-w-dialogu-i-likwidujace-bariery-cb528f4591811c94Pharma Surgeen2026-07-29T09:52:48.000ZZmiany tak, ale w dialogu i likwidujące barieryhttps://www.pharmaradar360.com/article/tasrif-pharmaceutical-announces-grant-of-second-u-s-patent-for-humanized-monoclo-048578436fdf4c11Pharma Surgeen2026-07-29T09:38:49.000ZTasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155)https://www.pharmaradar360.com/article/krystal-biotech-profitable-self-funding-and-loaded-with-optionality-nasdaq-krys-0094231ae8befaefPharma Surgeen2026-07-29T09:33:01.000ZKrystal Biotech: Profitable, Self-Funding, And Loaded With Optionality (NASDAQ:KRYS)https://www.pharmaradar360.com/article/vaccine-update-issue-373-july-2026-9786b36b1f448990Pharma Surgeen2026-07-29T09:24:10.000ZVaccine update: issue 373, July 2026https://www.pharmaradar360.com/article/czechia-looks-to-irish-eu-presidency-to-advance-biotech-act-71a3ed32f6165e1aPharma Surgeen2026-07-29T09:22:30.000ZCzechia looks to Irish EU presidency to advance Biotech Acthttps://www.pharmaradar360.com/article/pnc-financial-services-group-inc-has-2-88-million-stock-holdings-in-teva-pharmac-fdea3d2fab72c23aPharma Surgeen2026-07-29T09:18:14.000ZPNC Financial Services Group Inc. Has $2.88 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/guidance-digital-mental-health-technology-qualification-and-classification-e2a4c7cf41aed2d8Pharma Surgeen2026-07-29T09:00:07.000ZGuidance: Digital mental health technology: qualification and classificationhttps://www.pharmaradar360.com/article/guidance-ambient-voice-technology-enabled-products-621b64a261993136Pharma Surgeen2026-07-29T09:00:07.000ZGuidance: Ambient voice technology-enabled productshttps://www.pharmaradar360.com/article/what-trump-s-200-tariff-threat-on-generics-means-to-pharmaceutical-industry-4ec005321e580e68Pharma Surgeen2026-07-29T08:40:32.000ZWhat Trump’s 200% tariff threat on generics means to pharmaceutical industryhttps://www.pharmaradar360.com/article/novo-pharmatech-ceo-rapid-change-in-the-pharmaceutical-industry-is-placing-new-d-75eb428e92fcd3dePharma Surgeen2026-07-29T08:37:00.000ZNovo Pharmatech CEO: Rapid change in the pharmaceutical industry is placing new demands on managementhttps://www.pharmaradar360.com/article/the-va-could-help-america-win-the-biotechnology-race-with-china-6905c218ebce5341Pharma Surgeen2026-07-29T08:34:07.000ZThe VA could help America win the biotechnology race with Chinahttps://www.pharmaradar360.com/article/in-the-biotech-industry-a-most-wanted-fugitive-was-long-hiding-in-plain-sight-f78b9c8eaa225647Pharma Surgeen2026-07-29T08:33:34.000ZIn the biotech industry, a most-wanted fugitive was long hiding in plain sighthttps://www.pharmaradar360.com/article/communicable-disease-outbreak-management-guidance-01d44b0203a04ae5Pharma Surgeen2026-07-29T08:30:03.000ZCommunicable disease outbreak management guidancehttps://www.pharmaradar360.com/article/8-5d556bb5ea935863Pharma Surgeen2026-07-29T08:30:00.000Z令和8年熊本地震による被害への支援についてhttps://www.pharmaradar360.com/article/support-for-areas-affected-by-the-2026-kumamoto-prefecture-earthquake-e5b7d65746aac4c8Pharma Surgeen2026-07-29T08:30:00.000ZSupport for Areas Affected by the 2026 Kumamoto Prefecture Earthquakehttps://www.pharmaradar360.com/article/la-aemps-concede-los-v-premios-pran-2026-a-nueve-iniciativas-frente-a-la-resiste-1e5e2f380b0c42e3Pharma Surgeen2026-07-29T08:28:47.000ZLa AEMPS concede los V Premios PRAN 2026 a nueve iniciativas frente a la resistencia a los antimicrobianoshttps://www.pharmaradar360.com/article/does-legend-biotech-s-legn-ceo-exit-reshape-confidence-in-its-cell-therapy-expan-45420c677f65b71dPharma Surgeen2026-07-29T08:21:55.000ZDoes Legend Biotech’s (LEGN) CEO Exit Reshape Confidence In Its Cell Therapy Expansion Strategy?https://www.pharmaradar360.com/article/regulatory-round-up-29-july-2026-41aee1be3460438bPharma Surgeen2026-07-29T08:20:39.000ZRegulatory round-up: 29 July 2026https://www.pharmaradar360.com/article/rtw-biotech-s-portfolio-company-completes-merger-with-vyne-therapeutics-34a752bee5ede95aPharma Surgeen2026-07-29T08:08:26.000ZRTW Biotech's Portfolio Company Completes Merger with Vyne Therapeuticshttps://www.pharmaradar360.com/article/handling-manufacturer-investigation-reports-for-medical-devices-and-ivds-b20515875324179bPharma Surgeen2026-07-29T08:05:30.000ZHandling Manufacturer Investigation Reports for Medical Devices and IVDshttps://www.pharmaradar360.com/article/aids-2026-some-pieces-falling-into-place-for-monthly-hiv-prevention-pill-but-key-97f3e4d173acaeb4Pharma Surgeen2026-07-29T08:03:05.000ZAIDS 2026: Some pieces falling into place for monthly HIV prevention pill, but key data not yet inhttps://www.pharmaradar360.com/article/mumbai-s-elite-clubs-under-scanner-fda-suspends-food-licences-of-five-iconic-clu-7d07ee33109e1f06Pharma Surgeen2026-07-29T07:46:00.000ZMumbai's elite clubs under scanner: FDA suspends food licences of five iconic clubs over serious hygiene violationshttps://www.pharmaradar360.com/article/potential-retatrutide-benefits-you-should-know-about-ac72bb2e3d85d358Pharma Surgeen2026-07-29T07:41:03.000ZPotential Retatrutide Benefits You Should Know Abouthttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-shares-purchased-by-adar1-capital-manage-5aee996cfb611dbbPharma Surgeen2026-07-29T07:18:08.000ZTeva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by ADAR1 Capital Management LLChttps://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-tre-19edeb0428ff1b00Pharma Surgeen2026-07-29T07:00:00.000ZAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areatahttps://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-tre-3f613233d05ea555Pharma Surgeen2026-07-29T07:00:00.000ZAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligohttps://www.pharmaradar360.com/article/12-funding-rounds-that-show-where-apac-biotech-capital-is-going-dbbb6ea00ab42674Pharma Surgeen2026-07-29T06:57:42.000Z12 Funding Rounds That Show Where APAC Biotech Capital Is Goinghttps://www.pharmaradar360.com/article/atea-s-bemnifosbuvir-ruzasvir-meets-endpoints-in-phase-3-hepatitis-c-trial-5223bcf3ea5be180Pharma Surgeen2026-07-29T06:51:08.000ZAtea’s Bemnifosbuvir/Ruzasvir Meets Endpoints in Phase 3 Hepatitis C Trialhttps://www.pharmaradar360.com/article/long-covid-s-phase-3-reckoning-what-stimulate-icp-reveals-about-designing-trials-7dcf7c832a7ac3bfPharma Surgeen2026-07-29T06:51:08.000ZLong COVID’s Phase 3 Reckoning: What STIMULATE-ICP Reveals About Designing Trials for Diseases Medicine Can’t Yet Explainhttps://www.pharmaradar360.com/article/bacchus-sales-lift-dong-a-socio-holdings-to-record-q2-revenue-f7de227534d9ab2dPharma Surgeen2026-07-29T06:10:30.000ZBacchus sales lift Dong-A Socio Holdings to record Q2 revenuehttps://www.pharmaradar360.com/article/ingenia-therapeutics-sets-ipo-price-at-12-000-9934ccd0238344c0Pharma Surgeen2026-07-29T06:09:34.000ZIngenia Therapeutics sets IPO price at ₩12,000https://www.pharmaradar360.com/article/hanmi-pharm-s-q2-operating-profit-doubles-on-rosuzet-growth-eli-lilly-licensing-e55257d0456adc0dPharma Surgeen2026-07-29T06:09:26.000ZHanmi Pharm's Q2 operating profit doubles on Rosuzet growth, Eli Lilly licensing dealhttps://www.pharmaradar360.com/article/legend-biotech-legn-ceo-exit-tests-management-stability-around-its-car-t-multipl-3de2f469bfb75830Pharma Surgeen2026-07-29T06:08:00.000ZLegend Biotech (LEGN) CEO Exit Tests Management Stability Around Its CAR-T Multiple Myeloma Strategyhttps://www.pharmaradar360.com/article/aids-activists-slam-pharmaceutical-companies-greed-over-hiv-drug-2b95cb75891c88cbPharma Surgeen2026-07-29T06:05:26.000ZAIDS activists slam pharmaceutical companies’ greed over HIV drughttps://www.pharmaradar360.com/article/blister-packaging-market-expands-as-pharmaceutical-demand-and-sustainable-innova-a920ec3e09738e9fPharma Surgeen2026-07-29T05:58:00.000ZBlister Packaging Market Expands as Pharmaceutical Demand and Sustainable Innovation Drive Global Growthhttps://www.pharmaradar360.com/article/top-portage-biotech-alp-competitors-2026-f77a722fc11c05f7Pharma Surgeen2026-07-29T05:27:41.000ZTop Portage Biotech (ALP) Competitors 2026https://www.pharmaradar360.com/article/chugai-pharmaceutical-co-ltd-unsponsored-adr-otcmkts-chgcy-sees-large-growth-in-46ed2f26bb533c45Pharma Surgeen2026-07-29T05:23:42.000ZChugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Sees Large Growth in Short Interesthttps://www.pharmaradar360.com/article/uk-biotech-venture-investment-hits-five-year-high-a46145c699cd4e1fPharma Surgeen2026-07-29T05:03:27.000ZUK biotech venture investment hits five-year highhttps://www.pharmaradar360.com/article/hanmi-pharm-s-q2-operating-profit-doubles-on-rosuzet-growth-eli-lilly-licensing-e3750611cd1685fePharma Surgeen2026-07-29T04:47:37.000ZHanmi Pharm's Q2 operating profit doubles on Rosuzet growth, Eli Lilly licensing dealhttps://www.pharmaradar360.com/article/legend-biotech-legn-replaces-ceo-ying-huang-with-interim-chief-alan-bash-d973ebdfd515ef90Pharma Surgeen2026-07-29T04:27:58.000ZLegend Biotech (LEGN) Replaces CEO Ying Huang With Interim Chief Alan Bashhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-shenyang-xingqi-pharmaceutical-co-ltd-cla-40ce4e7c023a943aPharma Surgeen2026-07-29T03:30:03.000ZEnterprise value to revenue forward of Shenyang Xingqi Pharmaceutical Co., Ltd. Class A – SZSE:300573https://www.pharmaradar360.com/article/fda-suspends-food-licences-of-five-mumbai-clubs-over-hygiene-violations-ba18fa8b29d56b41Pharma Surgeen2026-07-29T03:25:53.000ZFDA suspends food licences of five Mumbai clubs over hygiene violationshttps://www.pharmaradar360.com/article/sinovac-biotech-ltd-revenue-breakdown-fwb-svq-c9312febf29466e3Pharma Surgeen2026-07-29T02:06:34.000ZSinovac Biotech Ltd. Revenue Breakdown – FWB:SVQhttps://www.pharmaradar360.com/article/fda-staff-reiterate-concerns-about-replimune-skin-cancer-treatment-f55b472671a2d631Pharma Surgeen2026-07-29T01:36:13.000ZFDA staff reiterate concerns about Replimune skin cancer treatmenthttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-syngen-biotech-co-ltd-tpex-8279-ec02fa2d857ef209Pharma Surgeen2026-07-29T01:25:04.000ZPrice to earnings forward of Syngen Biotech Co., Ltd. – TPEX:8279https://www.pharmaradar360.com/article/price-to-sales-forward-of-syngen-biotech-co-ltd-tpex-8279-21e2fd15c61c97edPharma Surgeen2026-07-29T01:19:57.000ZPrice to sales forward of Syngen Biotech Co., Ltd. – TPEX:8279https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-syngen-biotech-co-ltd-tpex-8279-9cab19deab384b97Pharma Surgeen2026-07-29T00:28:56.000ZEnterprise value to EBIT forward of Syngen Biotech Co., Ltd. – TPEX:8279https://www.pharmaradar360.com/article/price-to-book-forward-of-syngen-biotech-co-ltd-tpex-8279-dbcd929ceb87ad17Pharma Surgeen2026-07-29T00:26:43.000ZPrice to book forward of Syngen Biotech Co., Ltd. – TPEX:8279https://www.pharmaradar360.com/article/nkgen-biotech-inc-revenue-breakdown-otc-nkgnw-2ae6af42c538edddPharma Surgeen2026-07-29T00:16:10.000ZNKGen Biotech Inc. Revenue Breakdown – OTC:NKGNWhttps://www.pharmaradar360.com/article/biogen-filed-form-8-k-e9e52a450c319d08Pharma Surgeen2026-07-29T00:00:00.000ZBiogen filed Form 8-Khttps://www.pharmaradar360.com/article/otsuka-foods-to-launch-micro-magic-french-fries-black-pepper-a-new-flavor-for-ad-8f91c923bf7775faPharma Surgeen2026-07-29T00:00:00.000ZOtsuka Foods to Launch Micro Magic French Fries: Black Pepper A New Flavor for Adults, Microwavable in the Box, Perfect with Drinks In Stores across Japan from August 24, 2026https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-3c204c7d85528a9cPharma Surgeen2026-07-29T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-13fdc9339c701686Pharma Surgeen2026-07-29T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-c447c94ebe01b4fbPharma Surgeen2026-07-29T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-8d340d0f712f2567Pharma Surgeen2026-07-29T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-9207f83803ed11f1Pharma Surgeen2026-07-29T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-e6d51a3b92ad9111Pharma Surgeen2026-07-29T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-c29e138b151ee5a5Pharma Surgeen2026-07-29T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-04e9864f8fa520d4Pharma Surgeen2026-07-29T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-53a75985dd8993adPharma Surgeen2026-07-29T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-0dfc90e247884682Pharma Surgeen2026-07-29T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-e89dfbc94ab736d1Pharma Surgeen2026-07-29T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-d9dc0edb7cf1b326Pharma Surgeen2026-07-29T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-7db4c1040753ae01Pharma Surgeen2026-07-29T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-b3d45a5226db188dPharma Surgeen2026-07-29T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/notice-of-award-of-a-sole-source-cooperative-agreement-to-fund-the-public-health-57d4915d6e170dacPharma Surgeen2026-07-29T00:00:00.000ZNotice of Award of a Sole Source Cooperative Agreement To Fund the Public Health Foundationhttps://www.pharmaradar360.com/article/medical-devices-radiology-devices-classification-of-the-phase-changing-fiducial-4d452b7d356ad019Pharma Surgeen2026-07-29T00:00:00.000ZMedical Devices; Radiology Devices; Classification of the Phase-Changing Fiducial Marker for Radiation Therapyhttps://www.pharmaradar360.com/article/statement-of-organization-functions-and-delegations-of-authority-4d17606b21112b54Pharma Surgeen2026-07-29T00:00:00.000ZStatement of Organization, Functions, and Delegations of Authorityhttps://www.pharmaradar360.com/article/notice-of-diabetes-mellitus-interagency-coordinating-committee-meeting-33eb1556867c5e16Pharma Surgeen2026-07-29T00:00:00.000ZNotice of Diabetes Mellitus Interagency Coordinating Committee Meetinghttps://www.pharmaradar360.com/article/product-specific-guidances-revised-draft-guidances-for-industry-availability-b89b43d521f5fb72Pharma Surgeen2026-07-29T00:00:00.000ZProduct-Specific Guidances; Revised Draft Guidances for Industry; Availabilityhttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-c57b39084bc75bb2Pharma Surgeen2026-07-29T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/drug-label-update-aspercreme-lidocaine-no-mess-plus-lavender-8366bb2b745da40cPharma Surgeen2026-07-29T00:00:00.000ZDrug label update: Aspercreme Lidocaine No-Mess plus Lavenderhttps://www.pharmaradar360.com/article/cultural-competence-and-clinical-decision-making-among-nurses-in-the-philippines-049458620489d60fPharma Surgeen2026-07-29T00:00:00.000ZCultural Competence and Clinical Decision-Making among Nurses in the Philippineshttps://www.pharmaradar360.com/article/intravenous-ketamine-for-depressed-and-suicidal-adolescents-in-the-emergency-dep-1865bd09ec9b0288Pharma Surgeen2026-07-29T00:00:00.000ZIntravenous Ketamine for Depressed and Suicidal Adolescents in the Emergency Department: A Randomized Double-Blind Trialhttps://www.pharmaradar360.com/article/clinical-and-pathogenetic-interactions-between-metabolic-dysfunction-associated-8827ed4b48d9ba9bPharma Surgeen2026-07-29T00:00:00.000ZCLINICAL AND PATHOGENETIC INTERACTIONS BETWEEN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND INFLAMMATORY BOWEL DISEASES: THE ROLE OF METABOLIC DISORDERS, MICROBIOTA, AND SYSTEMIC INFLAMMATIONhttps://www.pharmaradar360.com/article/clinical-characteristics-antibiotic-resistance-patterns-and-factors-associated-w-7ffcebf9cf77e11aPharma Surgeen2026-07-29T00:00:00.000ZClinical characteristics, antibiotic resistance patterns, and factors associated with mortality in neonatal Serratia marcescens bloodstream infections: a single-center retrospective cohort studyhttps://www.pharmaradar360.com/article/comparative-analgesic-effects-of-lidocaine-dexmedetomidine-co-administration-in-e425720ff4282973Pharma Surgeen2026-07-29T00:00:00.000ZComparative analgesic effects of lidocaine–dexmedetomidine co-administration in major laparoscopic gynecologic surgery: a randomized controlled trialhttps://www.pharmaradar360.com/article/exposure-based-video-therapy-for-obsessive-compulsive-disorder-and-posttraumatic-0d6aee710fdc9ce8Pharma Surgeen2026-07-29T00:00:00.000ZExposure-Based Video Therapy for Obsessive-Compulsive Disorder and Posttraumatic Stress Disorderhttps://www.pharmaradar360.com/article/impact-of-foreign-institutional-investment-on-share-price-and-market-capitalisat-fb7725b542b6db6fPharma Surgeen2026-07-29T00:00:00.000ZImpact of Foreign Institutional Investment on Share Price and Market Capitalisation of Indian Pharmaceutical Companieshttps://www.pharmaradar360.com/article/analysis-of-clinical-indicators-in-pediatric-patients-with-acinetobacter-baumann-54e393c3ee391b73Pharma Surgeen2026-07-29T00:00:00.000ZAnalysis of Clinical Indicators in Pediatric Patients with Acinetobacter baumannii and Klebsiella pneumoniae Infectionshttps://www.pharmaradar360.com/article/preoperative-thyroid-hormone-ratios-and-complete-blood-count-cbc-derived-biomark-8f9104a12a7f2213Pharma Surgeen2026-07-29T00:00:00.000ZPreoperative Thyroid Hormone Ratios and Complete Blood Count (CBC)-Derived Biomarkers for Differentiating Benign Thyroid Nodules from Papillary Thyroid Carcinoma: A Retrospective Single-Center Case–Control Studyhttps://www.pharmaradar360.com/article/a-history-of-psychiatric-hospitalization-and-surgically-managed-facial-abscess-a-cbb16c30686b1f8ePharma Surgeen2026-07-29T00:00:00.000ZA History of Psychiatric Hospitalization and Surgically Managed Facial Abscess: An Observed-to-Expected Association Analysishttps://www.pharmaradar360.com/article/robotic-assisted-spinal-instrumentation-from-c1-to-s1-experience-of-a-uk-neurosu-48dba15ab61ce7aaPharma Surgeen2026-07-29T00:00:00.000ZRobotic-Assisted Spinal Instrumentation from C1 to S1 Experience of a UK Neurosurgical Tertiary Referral Centrehttps://www.pharmaradar360.com/article/basic-clinical-bidirectional-empowerment-synergistic-breakthrough-in-molecular-m-75ebac08216e6873Pharma Surgeen2026-07-29T00:00:00.000ZBasic Clinical Bidirectional Empowerment: Synergistic Breakthrough in Molecular Mechanisms and Clinical Management of Small Cell Cervical Carcinomahttps://www.pharmaradar360.com/article/refining-the-vision-of-clinical-bioenergetics-updated-aims-and-scope-for-an-evol-111a9d8bd72720b9Pharma Surgeen2026-07-29T00:00:00.000ZRefining the Vision of Clinical Bioenergetics: Updated Aims and Scope for an Evolving Fieldhttps://www.pharmaradar360.com/article/high-in-vitro-activity-of-the-novel-pleuromutilin-antibiotic-lefamulin-on-clinic-d323507093536b8fPharma Surgeen2026-07-29T00:00:00.000ZHigh In Vitro Activity of the Novel Pleuromutilin Antibiotic, Lefamulin, on Clinical Helicobacter pylori Isolateshttps://www.pharmaradar360.com/article/in-vitro-activity-of-imipenem-funobactam-against-clinical-isolates-of-gram-negat-90eb21f2a95a3a08Pharma Surgeen2026-07-29T00:00:00.000ZIn Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacillihttps://www.pharmaradar360.com/article/a-novel-clinical-perspective-on-subarachnoid-hemorrhage-complicated-by-myocardia-a454aec1fea97d18Pharma Surgeen2026-07-29T00:00:00.000ZA novel clinical perspective on subarachnoid hemorrhage complicated by myocardial injury: independent predictors and short-term prognostic assessmenthttps://www.pharmaradar360.com/article/clinical-determinants-of-survival-outcomes-and-acute-toxicity-after-adoptive-cel-a02bc052df804db3Pharma Surgeen2026-07-29T00:00:00.000ZClinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumorshttps://www.pharmaradar360.com/article/educational-attainment-and-drug-firm-innovation-7fd7e99712ca45c0Pharma Surgeen2026-07-29T00:00:00.000ZEducational Attainment and Drug Firm Innovationhttps://www.pharmaradar360.com/article/randomized-clinical-trials-and-real-world-clinical-practice-data-for-hr-positive-7f62efcee29c7679Pharma Surgeen2026-07-29T00:00:00.000ZRandomized clinical trials and real-world clinical practice data for HR positive/HER2 negative metastatic breast cancer: a critical analysis of the evidence base. A reviewhttps://www.pharmaradar360.com/article/mas-alla-del-0-respuesta-mantenida-a-quimioinmunoterapia-en-pd-l1-negativo-e3750f0f79fafb42Pharma Surgeen2026-07-29T00:00:00.000ZMás allá del 0%: respuesta mantenida a quimioinmunoterapia en PD-L1 negativohttps://www.pharmaradar360.com/article/inverted-takotsubo-cardiomyopathy-triggered-by-corticosteroid-administration-in-52613e1af3ce504bPharma Surgeen2026-07-29T00:00:00.000ZInverted Takotsubo Cardiomyopathy Triggered by Corticosteroid Administration in a Patient with Undiagnosed Pheochromocytomahttps://www.pharmaradar360.com/article/association-of-apoe-gene-expression-with-thyroid-dysfunction-inflammation-and-ni-f69204d561ead3a0Pharma Surgeen2026-07-29T00:00:00.000ZAssociation of APOE gene expression with thyroid dysfunction, inflammation, and nitrosative stress in cardiometabolic syndrome: a case–control studyhttps://www.pharmaradar360.com/article/fda-inspection-preparation-4cf19cf940a1e4adPharma Surgeen2026-07-29T00:00:00.000ZFDA Inspection Preparationhttps://www.pharmaradar360.com/article/humanitarian-use-devices-1fb9b0f0dcda8c99Pharma Surgeen2026-07-29T00:00:00.000ZHumanitarian-Use Deviceshttps://www.pharmaradar360.com/article/investigator-site-file-f9d215c9b11e85ecPharma Surgeen2026-07-29T00:00:00.000ZInvestigator Site Filehttps://www.pharmaradar360.com/article/data-management-70140cc7c444e80ePharma Surgeen2026-07-29T00:00:00.000ZData Managementhttps://www.pharmaradar360.com/article/clinical-trials-laws-and-regulations-016e862ee3365403Pharma Surgeen2026-07-29T00:00:00.000ZClinical Trials Laws and Regulationshttps://www.pharmaradar360.com/article/investigational-drug-compounding-vs-manufacturing-ba11523c7ed825b9Pharma Surgeen2026-07-29T00:00:00.000ZInvestigational Drug Compounding vs. Manufacturinghttps://www.pharmaradar360.com/article/medwatch-e7b75e14d904e6e3Pharma Surgeen2026-07-29T00:00:00.000ZMedWatchhttps://www.pharmaradar360.com/article/site-initiation-and-site-initiation-visit-siv-procedures-99a3a81028469d1aPharma Surgeen2026-07-29T00:00:00.000ZSite Initiation and Site Initiation Visit (SIV) Procedureshttps://www.pharmaradar360.com/article/introduction-5b877ac6e06b7d4ePharma Surgeen2026-07-29T00:00:00.000ZIntroductionhttps://www.pharmaradar360.com/article/psychological-outcomes-and-intention-to-use-following-an-8-week-virtual-reality-c726b44f2f4e0540Pharma Surgeen2026-07-29T00:00:00.000ZPsychological outcomes and intention to use following an 8-week virtual reality tennis training programme: a randomised controlled trial with exploratory mediation analysishttps://www.pharmaradar360.com/article/multi-omics-analysis-reveals-micb-promotes-cerebral-atherosclerosis-through-ftmt-e953a1c97b6c8e8aPharma Surgeen2026-07-29T00:00:00.000ZMulti-omics analysis reveals MICB promotes cerebral atherosclerosis through FTMT suppression in NK and plasma cellshttps://www.pharmaradar360.com/article/development-and-validation-of-the-analytical-method-for-determination-of-residua-5ad26176e1e527fcPharma Surgeen2026-07-29T00:00:00.000ZDevelopment and validation of the analytical method for determination of residual solvents (2-propanol and n-hexane) in the drug substance Inosine Pranobexhttps://www.pharmaradar360.com/article/construction-of-a-comprehensive-competency-evaluation-index-system-for-clinical-3738af9bde37991ePharma Surgeen2026-07-29T00:00:00.000ZConstruction of a comprehensive competency evaluation index system for clinical nursing instructors based on a multifaceted feedback modelhttps://www.pharmaradar360.com/article/prenatal-ultrasound-findings-associated-with-intrauterine-cmv-infection-a-multic-c29fe4deb071723bPharma Surgeen2026-07-29T00:00:00.000ZPrenatal ultrasound findings associated with intrauterine CMV infection: a multicenter retrospective analysis of clinical and sonographic featureshttps://www.pharmaradar360.com/article/oral-semaglutide-for-alcohol-use-disorder-a-randomized-clinical-trial-43bbd17e7a24e536Pharma Surgeen2026-07-29T00:00:00.000ZOral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/supplementary-table-s10-from-clinical-validation-of-tissue-and-liquid-companion-568bd8ffa66aec0ePharma Surgeen2026-07-29T00:00:00.000ZSupplementary Table S10 from Clinical Validation of Tissue and Liquid Companion Diagnostics for <i>BRAF</i> V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Studyhttps://www.pharmaradar360.com/article/supplementary-table-s11-from-clinical-validation-of-tissue-and-liquid-companion-1bfb97cafa938bd0Pharma Surgeen2026-07-29T00:00:00.000ZSupplementary Table S11 from Clinical Validation of Tissue and Liquid Companion Diagnostics for <i>BRAF</i> V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Studyhttps://www.pharmaradar360.com/article/supplementary-table-s3-from-clinical-validation-of-tissue-and-liquid-companion-d-896a2aff2f84e080Pharma Surgeen2026-07-29T00:00:00.000ZSupplementary Table S3 from Clinical Validation of Tissue and Liquid Companion Diagnostics for <i>BRAF</i> V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Studyhttps://www.pharmaradar360.com/article/supplementary-table-s9-from-clinical-validation-of-tissue-and-liquid-companion-d-dcf0f5a81cc9211dPharma Surgeen2026-07-29T00:00:00.000ZSupplementary Table S9 from Clinical Validation of Tissue and Liquid Companion Diagnostics for <i>BRAF</i> V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Studyhttps://www.pharmaradar360.com/article/table-3-from-clinical-validation-of-tissue-and-liquid-companion-diagnostics-for-36683b6cdbb57f29Pharma Surgeen2026-07-29T00:00:00.000ZTable 3 from Clinical Validation of Tissue and Liquid Companion Diagnostics for <i>BRAF</i> V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Studyhttps://www.pharmaradar360.com/article/clinical-justification-for-osteoporosis-investigation-transitioning-from-opportu-5ac54108315832c5Pharma Surgeen2026-07-29T00:00:00.000ZClinical justification for osteoporosis investigation: transitioning from opportunistic to diagnostic referrals from alternative forms of imaginghttps://www.pharmaradar360.com/article/diagnosis-of-traumatic-diaphragmatic-injury-remains-a-clinical-challenge-brief-r-2513aadc6f7ce58bPharma Surgeen2026-07-29T00:00:00.000ZDiagnosis of traumatic diaphragmatic injury remains a clinical challenge – Brief reporthttps://www.pharmaradar360.com/article/clinical-and-biomechanical-recovery-trajectories-during-anti-gravity-treadmill-a-0f7d71ffe0753363Pharma Surgeen2026-07-29T00:00:00.000ZClinical and biomechanical recovery trajectories during anti-gravity treadmill-assisted rehabilitation after complex lower-limb articular fractures: a prospective pilot cohort studyhttps://www.pharmaradar360.com/article/effects-of-psychosocial-stress-on-opioid-self-administration-in-healthy-particip-35177d0e89ab543ePharma Surgeen2026-07-29T00:00:00.000ZEffects of psychosocial stress on opioid self-administration in healthy participants: a randomized, placebo-controlled crossover trialhttps://www.pharmaradar360.com/article/development-and-pilot-evaluation-of-an-electronic-trigger-based-surveillance-mod-4c8e0723ba8f1174Pharma Surgeen2026-07-29T00:00:00.000ZDevelopment and pilot evaluation of an electronic trigger-based surveillance model for sedative-hypnotic drug misuse in a tertiary hospitalhttps://www.pharmaradar360.com/article/effect-of-ocean-sounds-played-during-retinopathy-of-prematurity-examinations-on-32eb7e236c69efb6Pharma Surgeen2026-07-29T00:00:00.000ZEffect of ocean sounds played during retinopathy of prematurity examinations on physiology, pain, and comfort levels: a randomized controlled trialhttps://www.pharmaradar360.com/article/a-randomised-controlled-trial-to-study-the-use-of-large-language-models-prompt-e-67cb4825988cf2b7Pharma Surgeen2026-07-29T00:00:00.000ZA Randomised Controlled Trial to Study the Use of Large Language Models Prompt Engineered with Socratic Methods on the Impact of Medical Students’ Learninghttps://www.pharmaradar360.com/article/signals-of-venous-thromboembolism-risk-from-drug-drug-interactions-involving-ben-36c9eac2f2bfb402Pharma Surgeen2026-07-29T00:00:00.000ZSignals of Venous Thromboembolism Risk from Drug–Drug Interactions Involving Benzodiazepines and Other Sedative Hypnotics: Self-Controlled Case Series Analyseshttps://www.pharmaradar360.com/article/assessment-of-prevalence-and-clinical-profile-and-risk-factors-for-pregnancy-rel-749e12b3f156111cPharma Surgeen2026-07-29T00:00:00.000ZAssessment of Prevalence and Clinical Profile and Risk Factors for Pregnancy-Related Acute Kidney Injury in a Tertiary Care Hospital in Indiahttps://www.pharmaradar360.com/article/erap1-rs27038-polymorphism-and-il-17a-in-radiographic-axial-spondyloarthritis-a-e6433978a4bb3c3bPharma Surgeen2026-07-29T00:00:00.000ZERAP1 rs27038 Polymorphism and IL-17A in Radiographic Axial Spondyloarthritis: A South Indian Case–Control Studyhttps://www.pharmaradar360.com/article/sexual-myths-and-self-consciousness-in-women-a-randomized-controlled-trial-on-th-99bee67efeea80b6Pharma Surgeen2026-07-29T00:00:00.000ZSexual Myths and Self-Consciousness in Women: A Randomized Controlled Trial on the Power of Educationhttps://www.pharmaradar360.com/article/comparison-of-accelerated-mri-protocol-approaches-for-clinical-assessment-of-the-0cc4ec9a027eb9c9Pharma Surgeen2026-07-29T00:00:00.000ZComparison of accelerated MRI protocol approaches for clinical assessment of the kneehttps://www.pharmaradar360.com/article/comparative-clinical-and-molecular-epidemiology-of-norovirus-in-hospitalized-gas-ea5324f6962c6f22Pharma Surgeen2026-07-29T00:00:00.000ZComparative Clinical and Molecular Epidemiology of Norovirus in Hospitalized Gastroenteritis Cases, Western India (2013‐2023)https://www.pharmaradar360.com/article/engineering-extracellular-vesicles-strategies-for-functional-modification-and-cl-51b52d6bdfbbe28aPharma Surgeen2026-07-29T00:00:00.000ZEngineering Extracellular Vesicles: Strategies for Functional Modification and Clinical Translationhttps://www.pharmaradar360.com/article/intelligent-automation-improved-efficiency-in-pharmacovigilance-safety-signal-as-6c29b1165f601d81Pharma Surgeen2026-07-29T00:00:00.000ZIntelligent Automation Improved Efficiency in Pharmacovigilance Safety Signal Assessmenthttps://www.pharmaradar360.com/article/in-adults-with-low-back-pain-with-modic-type-1-changes-and-disc-herniation-on-ma-a8ad1d42ce0e3e83Pharma Surgeen2026-07-29T00:00:00.000ZIn adults with low back pain with Modic type 1 changes and disc herniation on magnetic resonance imaging (MRI), what are the benefits and harms of antibiotic therapy compared with placebo?https://www.pharmaradar360.com/article/pharmacometric-evaluation-of-pre-referral-rectal-artesunate-in-children-with-sev-0fec6df4bc640627Pharma Surgeen2026-07-29T00:00:00.000ZPharmacometric evaluation of pre‐referral rectal artesunate in children with severe malariahttps://www.pharmaradar360.com/article/marsha-blackburn-threatens-lawsuit-over-dark-money-pac-ad-43ad49d031107504Pharma Surgeen2026-07-28T23:54:08.000ZMarsha Blackburn threatens lawsuit over dark money PAC adhttps://www.pharmaradar360.com/article/no-a-judge-did-not-rule-abortion-pills-are-safe-c82921f2e691141fPharma Surgeen2026-07-28T23:45:00.000ZNo a Judge Did Not Rule Abortion Pills are Safehttps://www.pharmaradar360.com/article/bb-biotech-ag-2026-q2-results-earnings-call-presentation-otcmkts-bbagf-2026-07-2-5edd656ea9049366Pharma Surgeen2026-07-28T23:07:11.000ZBB Biotech AG 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:BBAGF) 2026-07-28https://www.pharmaradar360.com/article/arkansas-suspends-enforcement-of-law-limiting-pharmaceutical-distribution-bde47dd0965c25b2Pharma Surgeen2026-07-28T22:57:00.000ZArkansas suspends enforcement of law limiting pharmaceutical distributionhttps://www.pharmaradar360.com/article/portage-biotech-alp-stock-trends-and-sentiment-2026-alp-30e8051ee934e3faPharma Surgeen2026-07-28T22:51:23.000ZPortage Biotech (ALP) Stock Trends and Sentiment 2026 $ALPhttps://www.pharmaradar360.com/article/black-bird-biotech-inc-revenue-breakdown-otc-bbbt-baecba98ea07f053Pharma Surgeen2026-07-28T22:27:13.000ZBLACK BIRD BIOTECH INC Revenue Breakdown – OTC:BBBThttps://www.pharmaradar360.com/article/fda-official-insists-u-s-food-supply-is-safe-as-cyclosporiasis-cases-hit-11-000-e2c9d6210f4e61f3Pharma Surgeen2026-07-28T22:10:00.000ZFDA official insists ‘U.S. food supply is safe’ as cyclosporiasis cases hit 11,000https://www.pharmaradar360.com/article/kobayashi-pharmaceutical-co-ltd-revenue-breakdown-tradegate-koy-7956a715383ca6a9Pharma Surgeen2026-07-28T21:55:26.000ZKobayashi Pharmaceutical Co., Ltd. Revenue Breakdown – TRADEGATE:KOYhttps://www.pharmaradar360.com/article/virginia-federal-judge-orders-fda-to-reconsider-abortion-pill-safety-regulations-da2fca9e769030caPharma Surgeen2026-07-28T21:50:01.000ZVirginia federal judge orders FDA to reconsider abortion pill safety regulationshttps://www.pharmaradar360.com/article/compass-pathways-the-psilocybin-biotech-leader-with-strong-momentum-nasdaq-cmps-44a79f4ecaadb6c7Pharma Surgeen2026-07-28T21:29:06.000ZCompass Pathways: The Psilocybin Biotech Leader With Strong Momentum (NASDAQ:CMPS)https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-underperforms-tuesday-when-compared-to-co-8df48ab1ed759244Pharma Surgeen2026-07-28T21:04:00.000ZWest Pharmaceutical Services Inc. stock underperforms Tuesday when compared to competitors despite daily gainshttps://www.pharmaradar360.com/article/elevatebio-inks-deal-to-supply-kyverna-s-car-t-cell-therapy-for-gmg-5825c24835f2e729Pharma Surgeen2026-07-28T20:03:36.000ZElevateBio inks deal to supply Kyverna’s CAR T-cell therapy for gMGhttps://www.pharmaradar360.com/article/keeping-drugs-free-of-contaminants-pharmaceutical-makers-filter-medications-thro-6d39e9a246fa82bePharma Surgeen2026-07-28T19:53:56.000ZKeeping drugs free of contaminants – pharmaceutical makers filter medications through tiny pores to keep them sterile and safehttps://www.pharmaradar360.com/article/biomarin-and-n-lorem-foundation-enter-collaboration-pharmexec-1b45dc10732aaf82Pharma Surgeen2026-07-28T19:48:04.000ZBioMarin and n-Lorem Foundation Enter Collaboration | PharmExechttps://www.pharmaradar360.com/article/kelun-biotech-advances-first-dual-payload-adc-into-clinical-trials-for-solid-tum-d2b823c7afaf8a7ePharma Surgeen2026-07-28T18:52:43.000ZKelun-Biotech Advances First Dual-Payload ADC into Clinical Trials for Solid Tumourshttps://www.pharmaradar360.com/article/biotech-subsidiary-raises-130-million-to-treat-this-painful-condition-c4c4fe67eb2a8906Pharma Surgeen2026-07-28T18:44:00.000ZBiotech subsidiary raises $130 million to treat this painful conditionhttps://www.pharmaradar360.com/article/jyong-biotech-expands-global-licensing-push-for-botanical-therapy-targeting-enla-a4e7585f2df27b95Pharma Surgeen2026-07-28T18:31:05.000ZJyong Biotech Expands Global Licensing Push for Botanical Therapy Targeting Enlarging BPH Markethttps://www.pharmaradar360.com/article/mumbai-s-clubs-face-fda-heat-cci-mig-and-others-lose-food-licences-cockroaches-f-f03df4687de7197aPharma Surgeen2026-07-28T18:04:41.000ZMumbai’s Clubs Face FDA Heat! CCI, MIG and Others Lose Food Licences: Cockroaches, Flies and Mouldy Food Foundhttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-shareholders-approve-corporate-governance-financing-measures-daae4d52b1d5420dPharma Surgeen2026-07-28T17:45:00.000ZVERAXA Biotech (VRXA) Shareholders Approve Corporate Governance, Financing Measureshttps://www.pharmaradar360.com/article/pharmaceutical-labels-4b95d5f6a20b6ce6Pharma Surgeen2026-07-28T17:31:00.000ZPharmaceutical Labelshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-stock-12-month-price-target-raised-to-19-0-cca4a4f3a85d367bPharma Surgeen2026-07-28T17:20:12.000ZTakeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.01, Implies 9% Upsidehttps://www.pharmaradar360.com/article/amylin-analogs-and-combination-therapies-clinical-trial-landscape-expands-as-15-4a08abcf44de774ePharma Surgeen2026-07-28T17:08:38.000ZAmylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsighthttps://www.pharmaradar360.com/article/fda-suspends-food-licences-of-five-mumbai-clubs-over-major-hygiene-food-safety-v-fe6594d8aeef407cPharma Surgeen2026-07-28T17:07:45.000ZFDA suspends food licences of five Mumbai clubs over major hygiene, food safety violationshttps://www.pharmaradar360.com/article/peli-biothermal-paxafe-partnership-signals-ai-powered-cold-chain-future-41865711f4989fc4Pharma Surgeen2026-07-28T17:06:01.000ZPeli BioThermal, PAXAFE Partnership Signals AI-Powered Cold Chain Futurehttps://www.pharmaradar360.com/article/developer-to-seek-approval-in-canada-for-als-treatment-aiding-survival-45bb93da654e973ePharma Surgeen2026-07-28T16:42:07.000ZDeveloper to seek approval in Canada for ALS treatment aiding survivalhttps://www.pharmaradar360.com/article/maharashtra-fda-suspends-licences-of-these-5-clubs-in-mumbai-over-food-safety-vi-a7dbc221eeb8d8f9Pharma Surgeen2026-07-28T16:08:24.000ZMaharashtra FDA Suspends Licences of These 5 Clubs in Mumbai Over Food Safety Violations; Check Names Herehttps://www.pharmaradar360.com/article/fda-panel-to-consider-previously-spurned-drugs-44b94a38143acbaaPharma Surgeen2026-07-28T16:00:00.000ZFDA panel to consider previously spurned drugshttps://www.pharmaradar360.com/article/taiwan-biotech-looks-outward-in-next-phase-of-growth-3f5aa9d905a233e7Pharma Surgeen2026-07-28T16:00:00.000ZTaiwan biotech looks outward in next phase of growthhttps://www.pharmaradar360.com/article/ono-pharmaceutical-partners-with-phylo-to-embed-agentic-ai-with-every-discovery-d1badd7aeb3202abPharma Surgeen2026-07-28T16:00:00.000ZOno Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientisthttps://www.pharmaradar360.com/article/recordati-solid-momentum-of-the-group-continues-first-half-2026-net-revenue-6-6-ceed42b29aa53f86Pharma Surgeen2026-07-28T15:55:53.000ZRECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7%https://www.pharmaradar360.com/article/piper-sandler-raises-teva-pharmaceutical-industries-nyse-teva-price-target-to-44-59f350b2778ee99fPharma Surgeen2026-07-28T15:37:35.000ZPiper Sandler Raises Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $44.00https://www.pharmaradar360.com/article/kalshi-and-polymarket-now-let-you-bet-on-drug-approvals-and-not-everyone-is-thri-02ceded2bd1c461cPharma Surgeen2026-07-28T15:09:53.000ZKalshi and Polymarket now let you bet on drug approvals, and not everyone is thrilled about ithttps://www.pharmaradar360.com/article/fedrigoni-addresses-evolving-pharmaceutical-label-industry-9922c9577815c224Pharma Surgeen2026-07-28T15:03:59.000ZFedrigoni addresses evolving pharmaceutical label industryhttps://www.pharmaradar360.com/article/biotech-division-of-greenland-mines-announces-issuance-of-patent-in-canada-for-t-0bc0eb26588295abPharma Surgeen2026-07-28T15:01:11.000ZBiotech Division of Greenland Mines Announces Issuance of Patent in Canada for the Klotho Gene Therapy Platform Technology for Alzheimer’s and Aginghttps://www.pharmaradar360.com/article/fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys-therapeuti-8f1463a6da0cd701Pharma Surgeen2026-07-28T15:00:17.000ZFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financinghttps://www.pharmaradar360.com/article/record-chinese-biotech-out-licensing-meets-rising-us-scrutiny-b825d005ceb57a9aPharma Surgeen2026-07-28T15:00:09.000ZRecord Chinese biotech out-licensing meets rising US scrutinyhttps://www.pharmaradar360.com/article/fda-action-against-mumbais-elite-clubs-cci-juhu-gymkhanas-mig-willingdon-lose-fs-b6e22a3fe82249c2Pharma Surgeen2026-07-28T14:54:57.000ZFDA Action Against Mumbais Elite Clubs: CCI, Juhu Gymkhanas, MIG, Willingdon Lose FSSAI Licenceshttps://www.pharmaradar360.com/article/gsk-cambridge-move-signals-shift-in-drug-scale-up-strategy-4a203e9a89242993Pharma Surgeen2026-07-28T14:50:08.000ZGSK Cambridge Move Signals Shift in Drug Scale-Up Strategyhttps://www.pharmaradar360.com/article/maplight-s-schizophrenia-candidate-clears-one-bar-but-misses-another-34d3c1d8817649cfPharma Surgeen2026-07-28T14:47:35.000ZMapLight's schizophrenia candidate clears one bar but misses anotherhttps://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-ultragenyx-pharmaceutical-rare-a-cebb543d446e1709Pharma Surgeen2026-07-28T14:42:37.000ZAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Danaher (DHR)https://www.pharmaradar360.com/article/leadership-changes-afoot-at-two-cgt-biotechs-eeb7c78b0f20f9a3Pharma Surgeen2026-07-28T14:37:26.000ZLeadership changes afoot at two CGT biotechshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-stock-12-month-price-target-raised-to-19-2-36ddddc12343fab6Pharma Surgeen2026-07-28T14:20:12.000ZTakeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.2, Implies 10% Upsidehttps://www.pharmaradar360.com/article/can-these-5-biotech-stocks-beat-wall-street-s-q2-estimates-92e305441879facePharma Surgeen2026-07-28T14:07:00.000ZCan These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?https://www.pharmaradar360.com/article/questex-s-fierce-pharma-unveils-fierce-pharma-week-s-2026-conference-program-exp-4df986349607d825Pharma Surgeen2026-07-28T14:05:17.000ZQuestex’s Fierce Pharma Unveils Fierce Pharma Week’s 2026 Conference Program, Explores What’s Next in the Pharmaceutical Industryhttps://www.pharmaradar360.com/article/fda-cracks-down-on-mumbai-clubs-for-food-safety-violations-b99d436573cc6f41Pharma Surgeen2026-07-28T14:00:22.000ZFDA Cracks Down On Mumbai Clubs For Food Safety Violationshttps://www.pharmaradar360.com/article/alnylam-s-stock-is-down-30-despite-a-booming-biotech-market-here-s-why-2be5df40cf7336b6Pharma Surgeen2026-07-28T14:00:00.000ZAlnylam’s stock is down 30% despite a booming biotech market. Here’s whyhttps://www.pharmaradar360.com/article/fda-grants-fast-track-designation-to-htx-001-for-nhcm-a8ea05d0e80576adPharma Surgeen2026-07-28T13:57:25.000ZFDA Grants Fast Track Designation to HTX-001 for nHCMhttps://www.pharmaradar360.com/article/chmp-backs-roche-s-susvimo-as-first-continuous-namd-therapy-57161bf215b1c98ePharma Surgeen2026-07-28T13:55:08.000ZCHMP backs Roche’s Susvimo as first continuous nAMD therapyhttps://www.pharmaradar360.com/article/peli-biothermal-partners-with-paxafe-to-redefine-pharmaceutical-cold-chain-intel-b5b83d7ff56d5d9aPharma Surgeen2026-07-28T13:53:00.000ZPeli BioThermal Partners with PAXAFE to Redefine Pharmaceutical Cold Chain Intelligencehttps://www.pharmaradar360.com/article/gsk-unveils-3-year-cost-saving-plan-to-fund-late-stage-r-d-move-research-hq-to-a-7a22bd2a232b90baPharma Surgeen2026-07-28T13:50:23.000ZGSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardhttps://www.pharmaradar360.com/article/china-s-biotech-rise-to-face-challenges-from-us-policy-responses-e5a9fe1e64dee365Pharma Surgeen2026-07-28T13:49:17.000ZChina’s biotech rise to face challenges from US policy responseshttps://www.pharmaradar360.com/article/nafdac-continued-enforcement-of-the-ban-on-sub-200ml-sachet-pet-bottle-alcoholic-7ae4497573e269b8Pharma Surgeen2026-07-28T13:46:24.000ZNAFDAC Continued Enforcement of the Ban on Sub-200ml Sachet & PET Bottle Alcoholic Products: Update on Nationwide Mop-Up Operation.https://www.pharmaradar360.com/article/brewing-up-biotech-tea-catechins-and-their-anti-aging-impact-0a4c84a4e0a6661fPharma Surgeen2026-07-28T13:44:15.000ZBrewing Up Biotech: Tea Catechins and Their Anti-Aging Impacthttps://www.pharmaradar360.com/article/brainstorm-appoints-former-fda-official-peter-pitts-executive-chairman-to-lead-p-356aea84f7ff6725Pharma Surgeen2026-07-28T13:42:51.000ZBrainStorm Appoints Former FDA Official Peter Pitts Executive Chairman to Lead Phase 3 ALS Strategyhttps://www.pharmaradar360.com/article/navigating-technology-transfer-in-pharma-and-biotech-4bb68da6177dd33fPharma Surgeen2026-07-28T13:32:41.000ZNavigating Technology Transfer in Pharma and Biotechhttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-buy-rating-from-bernstein-68babfe212822d92Pharma Surgeen2026-07-28T13:25:40.000ZSARTORIUS STEDIM BIOTECH : Buy rating from Bernsteinhttps://www.pharmaradar360.com/article/edison-issues-report-on-bb-biotech-bion-2faa051cc07bfa27Pharma Surgeen2026-07-28T13:20:54.000ZEdison issues report on BB Biotech (BION)https://www.pharmaradar360.com/article/an-eye-drug-biotech-banks-118m-and-stocks-its-executive-suite-d2ace487152d6c9ePharma Surgeen2026-07-28T13:16:36.000ZAn eye drug biotech banks $118M and stocks its executive suitehttps://www.pharmaradar360.com/article/stay-ahead-of-the-game-with-teva-pharmaceutical-industries-teva-q2-earnings-wall-ac50ff948e147659Pharma Surgeen2026-07-28T13:15:04.000ZStay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metricshttps://www.pharmaradar360.com/article/amgen-makes-case-to-continue-selling-drug-that-fda-links-to-deaths-29be1c75a6b766daPharma Surgeen2026-07-28T13:15:00.000ZAmgen makes case to continue selling drug that FDA links to deathshttps://www.pharmaradar360.com/article/fda-approves-first-over-the-counter-tylenol-naproxen-tab-for-12-hour-pain-relief-3d919f1f5dd371bdPharma Surgeen2026-07-28T13:13:45.000ZFDA approves first over-the-counter Tylenol & Naproxen tab for 12-hour pain reliefhttps://www.pharmaradar360.com/article/recce-pharmaceuticals-asx-rce-advances-phase-3-trials-and-mena-licensing-strateg-aa9ab7489126863fPharma Surgeen2026-07-28T13:10:00.000ZRecce Pharmaceuticals (ASX:RCE) Advances Phase 3 Trials and MENA Licensing Strategy as Commercial Pathway Developshttps://www.pharmaradar360.com/article/legend-biotech-names-interim-ceo-after-ying-huang-steps-down-0a20a47794754831Pharma Surgeen2026-07-28T13:01:34.000ZLegend Biotech names interim CEO after Ying Huang steps downhttps://www.pharmaradar360.com/article/pharmaceutical-ad-urges-viewers-to-fight-doctors-who-say-drug-not-right-for-them-1f0a06e0564589b2Pharma Surgeen2026-07-28T13:00:00.000ZPharmaceutical Ad Urges Viewers To Fight Doctors Who Say Drug Not Right For Themhttps://www.pharmaradar360.com/article/ai-in-pharmaceutical-manufacturing-executive-handbook-on-ai-readiness-digital-ma-6083d2578091c4e1Pharma Surgeen2026-07-28T13:00:00.000ZAI in Pharmaceutical Manufacturing: Executive Handbook on AI Readiness, Digital Maturity and Factory Transformationhttps://www.pharmaradar360.com/article/codexis-to-report-second-quarter-2026-financial-results-on-august-11-07926bc61e969f5fPharma Surgeen2026-07-28T13:00:00.000ZCodexis to Report Second Quarter 2026 Financial Results on August 11https://www.pharmaradar360.com/article/drug-alerts-and-statements-65b7066201a76f64Pharma Surgeen2026-07-28T12:53:50.000ZDrug Alerts and Statementshttps://www.pharmaradar360.com/article/boston-scientific-unveils-major-restructuring-plots-job-cuts-amid-savings-drive-1f6af1a4b38dcf44Pharma Surgeen2026-07-28T12:45:47.000ZBoston Scientific unveils major restructuring, plots job cuts amid savings drivehttps://www.pharmaradar360.com/article/botulism-clinical-and-public-health-management-3a0db3039f9af2daPharma Surgeen2026-07-28T12:44:39.000ZBotulism: clinical and public health managementhttps://www.pharmaradar360.com/article/vanguard-health-care-etf-outperforms-vaneck-biotech-on-returns-yield-and-fees-8c45baa13ad21d52Pharma Surgeen2026-07-28T12:44:28.000ZVanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Feeshttps://www.pharmaradar360.com/article/withdrawn-and-expired-guidances-drugs-1057bbfe24e27904Pharma Surgeen2026-07-28T12:38:01.000ZWithdrawn and Expired Guidances | Drugshttps://www.pharmaradar360.com/article/bioscience-and-health-technology-sector-statistics-2024-to-2025-ef58022ce55fc0a8Pharma Surgeen2026-07-28T12:35:20.000ZBioscience and health technology sector statistics 2024 to 2025https://www.pharmaradar360.com/article/eu-governments-set-to-address-biotech-and-economic-security-d2cf7d28cc2f6acePharma Surgeen2026-07-28T12:33:10.000ZEU governments set to address biotech and economic securityhttps://www.pharmaradar360.com/article/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-460f4d6b7e93e3caPharma Surgeen2026-07-28T12:30:00.000ZRelmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officerhttps://www.pharmaradar360.com/article/oak-hill-bio-announces-dosing-of-first-participant-in-beacon-phase-3-clinical-tr-11b0f7b266aeb1eaPharma Surgeen2026-07-28T12:18:36.000ZOak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndromehttps://www.pharmaradar360.com/article/dasher-neuroscience-completes-patient-enrollment-in-phase-2-global-clinical-tria-72e0a88c845436f0Pharma Surgeen2026-07-28T12:12:00.000ZDasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)https://www.pharmaradar360.com/article/chip-parkinson-on-direct-to-patient-s-big-year-8b84c93737b2160dPharma Surgeen2026-07-28T12:10:59.000ZChip Parkinson on Direct-to-Patient's Big Yearhttps://www.pharmaradar360.com/article/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-d462784826bc48acPharma Surgeen2026-07-28T12:05:00.000ZGSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UKhttps://www.pharmaradar360.com/article/five-gate-framework-proposed-for-india-uk-pharmaceutical-trade-agreement-impleme-01d17c36777b8700Pharma Surgeen2026-07-28T12:00:43.000ZFive-Gate Framework Proposed for India-UK Pharmaceutical Trade Agreement Implementationhttps://www.pharmaradar360.com/article/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum-plans-ann-ae63a73c0ac613eaPharma Surgeen2026-07-28T12:00:00.000ZGSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026https://www.pharmaradar360.com/article/oxygen-100-gas-cylinders-containing-commercial-grade-oxygen-5de27a73ae6106b6Pharma Surgeen2026-07-28T12:00:00.000ZOxygen 100%: Gas cylinders containing commercial grade oxygenhttps://www.pharmaradar360.com/article/iqecg-digital-ecg-a3d11dca5f20b962Pharma Surgeen2026-07-28T12:00:00.000ZIQecg® Digital ECGhttps://www.pharmaradar360.com/article/blanketrol-ii-115v-and-blanketrol-iii-115v-2f679ac48ef11dd0Pharma Surgeen2026-07-28T12:00:00.000ZBlanketrol® II 115V and Blanketrol® III 115Vhttps://www.pharmaradar360.com/article/a-webcast-will-carry-legend-biotech-s-q2-results-review-aug-11-0b053b3999db5775Pharma Surgeen2026-07-28T12:00:00.000ZA webcast will carry Legend Biotech's Q2 results review Aug. 11https://www.pharmaradar360.com/article/legend-biotech-to-host-investor-conference-call-on-second-quarter-2026-results-59523b86696e8d4fPharma Surgeen2026-07-28T12:00:00.000ZLegend Biotech to Host Investor Conference Call on Second Quarter 2026 Resultshttps://www.pharmaradar360.com/article/oak-hill-bio-announces-dosing-of-first-participant-in-97c7460313b876a0Pharma Surgeen2026-07-28T12:00:00.000ZOak Hill Bio Announces Dosing of First Participant inhttps://www.pharmaradar360.com/article/trevi-therapeutics-to-present-at-august-biotech-conferences-on-its-chronic-cough-649d39bbab7b9e26Pharma Surgeen2026-07-28T11:56:28.000ZTrevi Therapeutics to present at August biotech conferences on its chronic cough therapy Haduvio™https://www.pharmaradar360.com/article/jordanian-pharmaceutical-manufacturing-q2-profit-1-9-million-dinars-639626e8e10451a5Pharma Surgeen2026-07-28T11:48:10.000ZJordanian Pharmaceutical Manufacturing Q2 Profit 1.9 Million Dinarshttps://www.pharmaradar360.com/article/nasus-pharma-appoints-pharmaceutical-industry-veteran-brendan-p-o-grady-as-chief-7632a8c60fc44f0dPharma Surgeen2026-07-28T11:47:14.000ZNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'grady As Chief Executive Officer To Lead Strategic Growthhttps://www.pharmaradar360.com/article/nasus-pharma-appoints-pharmaceutical-industry-veteran-brendan-p-o-grady-as-chief-c929fdcd94694f1aPharma Surgeen2026-07-28T11:36:40.000ZNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growthhttps://www.pharmaradar360.com/article/gsk-beats-consensus-forecast-in-second-quarter-a25cb9dafd3f6ce7Pharma Surgeen2026-07-28T11:33:40.000ZGSK beats consensus forecast in second quarterhttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-buy-on-legend-biotech-stock-65-target-0ecd938d13d00a9fPharma Surgeen2026-07-28T11:33:00.000ZH.C. Wainwright reiterates Buy on Legend Biotech stock, $65 targethttps://www.pharmaradar360.com/article/la-aemps-valida-un-modelo-de-gobernanza-y-un-plan-de-accion-para-facilitar-la-ap-674d611b8ecc5782Pharma Surgeen2026-07-28T11:32:00.000ZLa AEMPS valida un modelo de gobernanza y un plan de acción para facilitar la aplicación del reglamento sobre evaluación de tecnologías sanitariashttps://www.pharmaradar360.com/article/nasus-pharma-appoints-pharmaceutical-industry-veteran-brendan-p-o-grady-as-chief-98bf54978b0d70d5Pharma Surgeen2026-07-28T11:31:42.000ZNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growthhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-is-rubric-capital-management-lp-s-4th-la-e9fd041a03e5bedePharma Surgeen2026-07-28T11:31:19.000ZTeva Pharmaceutical Industries Ltd. $TEVA is Rubric Capital Management LP's 4th Largest Positionhttps://www.pharmaradar360.com/article/grace-therapeutics-says-fda-minutes-confirm-no-clinical-safety-or-efficacy-defic-785915d37d6da7e0Pharma Surgeen2026-07-28T11:13:00.000ZGrace Therapeutics Says FDA Minutes Confirm No Clinical Safety or Efficacy Deficiencies in GTx-104 Review, Advances Dual-Source Manufacturing Plan Toward NDA Resubmissionhttps://www.pharmaradar360.com/article/atea-pharmaceuticals-reports-positive-phase-3-c-beyond-results-for-bemnifosbuvir-b672798e164a69aaPharma Surgeen2026-07-28T11:13:00.000ZAtea Pharmaceuticals Reports Positive Phase 3 C-BEYOND Results for Bemnifosbuvir/Ruzasvir in Hepatitis C, Achieving Non-Inferiority to Epclusahttps://www.pharmaradar360.com/article/gsk-s-licensor-hansoh-pharma-announces-positive-results-from-a-second-phase-iii-c71f835e3515377bPharma Surgeen2026-07-28T11:00:41.000ZGSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in Chinahttps://www.pharmaradar360.com/article/grace-therapeutics-advances-second-u-s-manufacturing-route-for-gtx-104-855e8a8efb43debePharma Surgeen2026-07-28T11:00:00.000ZGrace Therapeutics Advances Second U.S. Manufacturing Route for GTx-104https://www.pharmaradar360.com/article/field-safety-notices-20-to-24-july-2026-69b19fa2554c8c6aPharma Surgeen2026-07-28T10:57:23.000ZField Safety Notices: 20 to 24 July 2026https://www.pharmaradar360.com/article/anmat-establece-la-condicion-de-venta-libre-para-diez-ingredientes-farmaceuticos-4cc80aafc61a14dbPharma Surgeen2026-07-28T10:57:20.000ZANMAT establece la condición de venta libre para diez ingredientes farmacéuticos activoshttps://www.pharmaradar360.com/article/keeping-technology-focused-on-what-matters-most-people-and-purpose-b68c638a5224e8ccPharma Surgeen2026-07-28T10:54:57.000ZKeeping technology focused on what matters most – People and purposehttps://www.pharmaradar360.com/article/insiders-in-kane-biotech-still-down-40-on-ca-1-70m-investment-0a561a9fc280cbf5Pharma Surgeen2026-07-28T10:41:41.000ZInsiders In Kane Biotech Still Down 40% On CA$1.70m Investmenthttps://www.pharmaradar360.com/article/sihuan-pharmaceutical-holdings-group-sehk-460-looks-pricey-on-2026-earnings-guid-45923f119668783aPharma Surgeen2026-07-28T10:29:36.000ZSihuan Pharmaceutical Holdings Group (SEHK:460) Looks Pricey On 2026 Earnings Guidancehttps://www.pharmaradar360.com/article/2-2026-3d4545abaa6970e3Pharma Surgeen2026-07-28T10:23:46.000ZΝέα ΣΥΦΑ 2ου Τριμήνου 2026 _ Τιμολόγηση Φαρμακευτικών Προϊόντωνhttps://www.pharmaradar360.com/article/china-s-biotech-rise-to-face-challenges-from-us-policy-responses-e2d1068d210304aePharma Surgeen2026-07-28T10:18:45.000ZChina's biotech rise to face challenges from US policy responseshttps://www.pharmaradar360.com/article/singapore-hst-medical-acquired-by-kowa-pharmaceutical-asia-to-scale-health-brand-4d940b621e14414cPharma Surgeen2026-07-28T10:15:09.000ZSingapore: HST Medical acquired by Kowa Pharmaceutical Asia to scale health brands globallyhttps://www.pharmaradar360.com/article/preliminary-trial-results-suggest-a-path-to-a-safer-alzheimer-s-treatment-a7ed38bb8868b3c4Pharma Surgeen2026-07-28T10:03:32.000ZPreliminary trial results suggest a path to a safer Alzheimer’s treatmenthttps://www.pharmaradar360.com/article/integrated-care-pathway-in-individuals-with-long-covid-stimulate-icp-a-cluster-r-0337d2c2ee35d421Pharma Surgeen2026-07-28T09:50:54.000ZIntegrated care pathway in individuals with Long COVID: STIMULATE-ICP, a cluster-randomized, phase 3 trialhttps://www.pharmaradar360.com/article/eaa57ee999d15ac1Pharma Surgeen2026-07-28T09:38:36.000ZΤιμολόγηση Νέων _ Τελικά Προϊόντα Φαρμακευτικής Κάνναβης _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/sbi-securities-starts-takeda-pharmaceutical-at-neutral-with-5-400-yen-price-targ-5c3b127791d9ac69Pharma Surgeen2026-07-28T09:17:50.000ZSBI Securities Starts Takeda Pharmaceutical at Neutral with 5,400 Yen Price Targethttps://www.pharmaradar360.com/article/parkinson-s-disease-drug-trial-extended-following-early-findings-78961416ed0f1884Pharma Surgeen2026-07-28T09:16:55.000ZParkinson’s Disease Drug Trial Extended Following Early Findingshttps://www.pharmaradar360.com/article/hlb-pep-registers-antidiuretic-hormone-treatment-vasopressin-api-with-u-s-fda-d3f4855c011385eePharma Surgeen2026-07-28T09:08:39.000ZHLB PEP registers antidiuretic hormone treatment ‘Vasopressin’ API with U.S. FDAhttps://www.pharmaradar360.com/article/jyong-biotech-highlights-multi-billion-dollar-global-bph-market-opportunity-and-c88d4ea5fc9f7c7fPharma Surgeen2026-07-28T08:49:42.000ZJyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnershipshttps://www.pharmaradar360.com/article/biotech-growth-makes-14-times-return-on-forte-biosciences-accepting-2-2bn-bid-fr-3355ce7fd1f4f0c7Pharma Surgeen2026-07-28T08:48:48.000ZBiotech Growth makes 14-times return on Forte Biosciences accepting $2.2bn bid from Argenx SEhttps://www.pharmaradar360.com/article/from-lost-cause-to-gold-rush-biotechs-swarm-to-cure-aatd-435d38579c315829Pharma Surgeen2026-07-28T08:33:21.000ZFrom ‘lost cause’ to gold rush: Biotechs swarm to cure AATDhttps://www.pharmaradar360.com/article/kelun-biotech-receives-trial-notice-for-dual-payload-adc-b23bf542edf83d10Pharma Surgeen2026-07-28T08:16:21.000ZKelun-Biotech receives trial notice for dual-payload ADChttps://www.pharmaradar360.com/article/apnimed-prepares-ipo-as-mass-biotechs-near-record-year-9da8da9f335fabbbPharma Surgeen2026-07-28T08:14:00.000ZApnimed prepares IPO as Mass. biotechs near record yearhttps://www.pharmaradar360.com/article/hanmi-pharmaceutical-posts-q2-profit-surge-on-lilly-deal-and-strong-korea-sales-d02e49346854eb57Pharma Surgeen2026-07-28T07:53:00.000ZHanmi Pharmaceutical posts Q2 profit surge on Lilly deal and strong Korea sales - CHOSUNBIZhttps://www.pharmaradar360.com/article/hanmi-pharmaceutical-q2-operating-profit-surges-116-9-7053244ddcdc9ecdPharma Surgeen2026-07-28T07:48:43.000ZHanmi Pharmaceutical Q2 Operating Profit Surges 116.9%https://www.pharmaradar360.com/article/poornima-restaurant-iconic-fort-udupi-eatery-loses-food-licence-after-maharashtr-c210150f095fd02ePharma Surgeen2026-07-28T07:38:54.000ZPoornima Restaurant, Iconic Fort Udupi Eatery, Loses Food Licence After Maharashtra FDA Finds Serioushttps://www.pharmaradar360.com/article/gerresheimer-doubles-china-injectable-packaging-capacity-with-new-plant-f0d749a3fef7aa91Pharma Surgeen2026-07-28T07:38:09.000ZGerresheimer doubles China injectable packaging capacity with new planthttps://www.pharmaradar360.com/article/abl-bio-wins-korea-approval-for-phase-1-trial-of-bispecific-immuno-oncology-drug-ee30ef53a661bc58Pharma Surgeen2026-07-28T07:25:44.000ZABL Bio Wins Korea Approval for Phase 1 Trial of Bispecific Immuno-Oncology Drug ABL503https://www.pharmaradar360.com/article/natural-beauty-ingredients-get-biotech-rebuild-as-crop-scarcity-rises-e7304177d81aaae4Pharma Surgeen2026-07-28T07:24:04.000ZNatural beauty ingredients get biotech rebuild as crop scarcity riseshttps://www.pharmaradar360.com/article/el-consumo-de-antibioticos-en-espana-retoma-la-senda-de-descenso-y-cae-cerca-del-961beec465b4ddcbPharma Surgeen2026-07-28T07:16:15.000ZEl consumo de antibióticos en España retoma la senda de descenso y cae cerca del 19% desde 2015https://www.pharmaradar360.com/article/us-pharma-giant-to-pay-out-7-9-billion-over-baby-powder-lawsuits-d462815da2f95ee7Pharma Surgeen2026-07-28T06:58:37.000ZUS pharma giant to pay out $7.9 billion over baby powder lawsuitshttps://www.pharmaradar360.com/article/pacira-completes-manufacturing-transition-in-pcrx-201-phase-2-trial-546fea5f19ca1b80Pharma Surgeen2026-07-28T06:56:04.000ZPacira Completes Manufacturing Transition in PCRX-201 Phase 2 Trialhttps://www.pharmaradar360.com/article/biotech-growth-trust-notes-2-2-billion-acquisition-of-forte-biosciences-b818f353a6dd8671Pharma Surgeen2026-07-28T06:44:23.000ZBiotech Growth Trust Notes $2.2 Billion Acquisition Of Forte Bioscienceshttps://www.pharmaradar360.com/article/egsedi-c2efccec61d6d7d8Pharma Surgeen2026-07-28T06:21:07.000ZΕΠΙΚΟΙΝΩΝΙΑ ΓΙΑ ΕΛΛΕΙΨΗ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ ΤEGSEDIhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-is-down-6-0-after-raising-2026-outlook-and-expa-19a614f4e1e534a1Pharma Surgeen2026-07-28T06:01:19.000ZWest Pharmaceutical Services (WST) Is Down 6.0% After Raising 2026 Outlook and Expanding Daikyo Dealhttps://www.pharmaradar360.com/article/south-korea-s-fda-sets-first-concrete-clinical-trial-exemption-rules-for-medical-4730efbacc2fa681Pharma Surgeen2026-07-28T05:56:00.000ZSouth Korea's FDA Sets First Concrete Clinical Trial Exemption Rules for Medical AI, Expands Special Provisions for Generative AIhttps://www.pharmaradar360.com/article/haisco-pharmaceutical-group-co-ltd-class-a-revenue-breakdown-szse-002653-93c4279019a6939cPharma Surgeen2026-07-28T05:10:18.000ZHaisco Pharmaceutical Group Co. Ltd. Class A Revenue Breakdown – SZSE:002653https://www.pharmaradar360.com/article/sls-stock-hits-1-month-low-on-china-arbitration-blow-retail-bulls-call-it-a-noth-a0f22d1815ba124fPharma Surgeen2026-07-28T05:06:00.000ZSLS Stock Hits 1-Month Low On China Arbitration Blow — Retail Bulls Call It A ‘Nothingburger’ Ahead Of AML Readouthttps://www.pharmaradar360.com/article/fda-expert-panel-backs-compounding-of-six-peptides-039f5c91b35393caPharma Surgeen2026-07-28T05:03:55.000ZFDA Expert Panel Backs Compounding of Six Peptideshttps://www.pharmaradar360.com/article/fda-expert-panel-backs-compounding-of-six-peptides-3ceac973b972eb63Pharma Surgeen2026-07-28T05:01:42.000ZFDA Expert Panel Backs Compounding of Six Peptideshttps://www.pharmaradar360.com/article/fda-suspends-license-of-mumbai-s-six-decade-old-udupi-eatery-poornima-restaurant-0105269ecf4c7dffPharma Surgeen2026-07-28T04:51:11.000ZFDA suspends license of Mumbai’s six-decade-old Udupi eatery Poornima Restauranthttps://www.pharmaradar360.com/article/sihuan-pharmaceutical-updates-bermuda-registered-office-address-89e6475c9152ddf6Pharma Surgeen2026-07-28T04:50:52.000ZSihuan Pharmaceutical Updates Bermuda Registered Office Addresshttps://www.pharmaradar360.com/article/aekyung-industrial-and-dong-sung-pharmaceutical-collaborate-with-fudan-universit-53bb7c7f8b5fb40cPharma Surgeen2026-07-28T04:40:00.000ZAekyung Industrial and Dong Sung Pharmaceutical Collaborate with Fudan University on Dermatology and Beauty Researchhttps://www.pharmaradar360.com/article/viral-acne-removal-cream-brand-set-to-launch-ipo-a-breakthrough-moment-for-the-i-23690aab71ba4507Pharma Surgeen2026-07-28T04:32:28.000ZViral Acne Removal Cream Brand Set to Launch IPO: A Breakthrough Moment for the Internet-Famous Skincare Labelhttps://www.pharmaradar360.com/article/global-pharmaceutical-surfactants-market-size-share-worth-usd-6-93-billion-by-20-4f4ee897724ba944Pharma Surgeen2026-07-28T04:30:00.000ZGlobal Pharmaceutical Surfactants Market Size/Share Worth USD 6.93 Billion by 2035 at a 4.42% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)https://www.pharmaradar360.com/article/sihuan-pharmaceutical-flags-217-profit-surge-on-medical-aesthetics-and-portfolio-a14d079bd78c542cPharma Surgeen2026-07-28T04:18:16.000ZSihuan Pharmaceutical Flags 217% Profit Surge on Medical Aesthetics and Portfolio Gainshttps://www.pharmaradar360.com/article/interview-how-tragedy-changed-the-fda-bcce3fbc45661da6Pharma Surgeen2026-07-28T04:01:29.000ZInterview: How Tragedy Changed the FDAhttps://www.pharmaradar360.com/article/fda-advisers-dismiss-safety-warnings-back-4-peptide-treatments-4f55b7d9383d5007Pharma Surgeen2026-07-28T04:00:00.000ZFDA Advisers Dismiss Safety Warnings, Back 4 Peptide Treatmentshttps://www.pharmaradar360.com/article/arrowhead-pharmaceuticals-completes-enrollment-in-global-phase-3-yosemite-study-04b9ba00c1862d2ePharma Surgeen2026-07-28T03:34:04.000ZArrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemiahttps://www.pharmaradar360.com/article/using-compounded-glp-1-drugs-here-s-what-doctors-want-you-to-know-b4914d175b8aa4f0Pharma Surgeen2026-07-28T03:30:00.000ZUsing Compounded GLP-1 Drugs? Here's What Doctors Want You to Knowhttps://www.pharmaradar360.com/article/should-teva-s-branded-drug-pivot-and-duvakitug-bet-reshape-how-teva-investors-vi-eb53333f9af164cfPharma Surgeen2026-07-28T03:11:15.000ZShould Teva’s Branded-Drug Pivot and Duvakitug Bet Reshape How TEVA Investors View Earnings Power?https://www.pharmaradar360.com/article/ibento-ibento-asean-japan-medical-devices-regulatory-symposium-2026-report-75a24348222fa8f5Pharma Surgeen2026-07-28T03:00:00.000Z[IBENTO][IBENTO]ASEAN-Japan Medical Devices Regulatory Symposium 2026 Reporthttps://www.pharmaradar360.com/article/argent-biopharma-finalizes-us-5-5-million-cannepil-licensing-deal-with-splash-be-54cf2b0f1a21e5c3Pharma Surgeen2026-07-28T02:45:00.000ZArgent BioPharma Finalizes US$5.5 Million CannEpil® Licensing Deal with Splash Beverage Group, Eliminates Major Debthttps://www.pharmaradar360.com/article/otsuka-to-present-pivotal-two-year-egfr-results-from-the-phase-3-visionary-trial-45d4faa6860e29f7Pharma Surgeen2026-07-28T02:21:37.000ZOtsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026https://www.pharmaradar360.com/article/selling-us-5-8m-of-stock-was-lucrative-decision-for-genscript-biotech-insiders-182b229f29279dfaPharma Surgeen2026-07-28T02:05:42.000ZSelling US$5.8m Of Stock Was Lucrative Decision For Genscript Biotech Insidershttps://www.pharmaradar360.com/article/study-examined-the-effectiveness-of-antibody-injection-simulations-d34133ed25660b67Pharma Surgeen2026-07-28T01:48:00.000ZStudy Examined The Effectiveness of Antibody Injection Simulationshttps://www.pharmaradar360.com/article/yubo-international-biotech-limited-revenue-breakdown-otc-ybgj-b0e56438f8fb47baPharma Surgeen2026-07-28T01:40:49.000ZYubo International Biotech Limited Revenue Breakdown – OTC:YBGJhttps://www.pharmaradar360.com/article/restricting-illicit-synthetic-drugs-a-complicated-challenge-590a0af845fe4228Pharma Surgeen2026-07-28T01:35:31.000ZRestricting illicit synthetic drugs a complicated challengehttps://www.pharmaradar360.com/article/bayer-opens-global-innovation-network-to-korean-biotech-startups-6a04ee79e66da6a2Pharma Surgeen2026-07-28T01:31:14.000ZBayer opens global innovation network to Korean biotech startupshttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-group-units-thailand-depositery-receipts-repr-0-01-sh-f40d0caa1fb0586aPharma Surgeen2026-07-28T01:07:14.000ZHansoh Pharmaceutical Group Units Thailand Depositery Receipts Repr 0.01 Shhttps://www.pharmaradar360.com/article/aribio-wraps-up-global-phase-3-trial-of-ar1001-sets-stage-for-topline-results-5df0fecae9209a84Pharma Surgeen2026-07-28T01:01:35.000ZAriBio wraps up global phase 3 trial of AR1001, sets stage for topline resultshttps://www.pharmaradar360.com/article/south-korea-transfers-liver-organoid-tech-to-daewoong-accelerates-animal-test-sh-9de94ecf022485e1Pharma Surgeen2026-07-28T00:38:00.000ZSouth Korea transfers liver organoid tech to Daewoong, accelerates animal-test shift - CHOSUNBIZhttps://www.pharmaradar360.com/article/aribio-completes-global-phase-3-alzheimer-trial-readies-topline-results-chosunbi-8071d7c86349f79fPharma Surgeen2026-07-28T00:07:00.000ZAribio completes global phase 3 Alzheimer trial, readies topline results - CHOSUNBIZhttps://www.pharmaradar360.com/article/johnson-johnson-filed-form-8-k-32182fad9363497dPharma Surgeen2026-07-28T00:00:00.000ZJohnson & Johnson filed Form 8-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-c7bc9dec2aad4875Pharma Surgeen2026-07-28T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/catering-menu-petros-love-at-first-bite-15f523f1017c07bbPharma Surgeen2026-07-28T00:00:00.000ZCatering Menu — Petros® Love at First Bitehttps://www.pharmaradar360.com/article/new-lung-preservation-machine-could-make-hundreds-of-unused-donor-lungs-availabl-e6869085d976c07dPharma Surgeen2026-07-28T00:00:00.000ZNew lung preservation machine could make hundreds of unused donor lungs available for transplanthttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-28T00:00:00.000ZView all news articles